...
首页> 外文期刊>Indian journal of orthopaedics >Role of Beta Tri-calcium Phosphate-based Composite Ceramic as Bone-Graft Expander in Masquelet's-Induced Membrane Technique
【24h】

Role of Beta Tri-calcium Phosphate-based Composite Ceramic as Bone-Graft Expander in Masquelet's-Induced Membrane Technique

机译:β-磷酸三钙基复合陶瓷作为骨接枝膨胀剂在Masquelet诱导膜技术中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Filling bone defect after debridement of infected nonunion is an orthopedic challenge. Since the volume of autologous bone graft available is limited, allograft, demineralized bone matrix, and calcium phosphate ceramic-based bone graft substitutes have come up as potential autograft expanders. This study was conducted to analyze the use of beta tri-calcium phosphate (B-TCP)-based composite ceramic as autologous bone-graft expander in the management of postinfective segmental gap nonunion of long bones managed with two-stage Masquelet's technique. Materials and Methods: 42 consecutive patients with postinfective segmental long bone defects of 4–12 cm managed with Masquelet's-induced membrane technique, operated between February 2012 and June 2015, were included in this prospective case series. During the second stage bone-grafting procedure, iliac crest autograft alone or mixed with B-TCP granules (ratio not exceeding 1:1) was used along with appropriate internal-fixation. Bony union (defined clinicoradiologically as ability to painlessly bear weight on affected limb without support along with bridging of 3 cortices on X-rays) was evaluated. Results: Union was achieved in 80.9% patients (34/42) with index bone grafting. 100% union rate was achieved in patients where only autograft was used (15/15) and in nonsmoker femoral nonunion patients with the use of B-TCP (13/13). The use of B-TCP was associated with higher rate of nonunion in smokers (6/8, 75%) and in tibial nonunions (4/9, 55.5%). All, but one, of 8 patients with nonunion, united after the second-bone grafting procedure. Conclusion: B-TCP is an efficacious and safe autologous bone graft expander in Masquelet's two-stage management of post infective segmental gap nonunion of long bones. Patients should be counseled regarding increased risk of nonunion and need for repeat grafting with its use, especially if they are smokers or site of involvement is tibia.
机译:背景:清创感染的骨不连后填充骨缺损是整形外科的挑战。由于可用的自体骨移植物的数量有限,同种异体移植物,脱矿质骨基质和磷酸钙陶瓷基骨移植物替代物已成为潜在的自体移植物扩张剂。本研究旨在分析使用β-磷酸三钙(B-TCP)基复合陶瓷作为自体骨移植扩展剂在两阶段Masquelet技术处理的长骨感染后节段性骨不愈合的管理中的应用。材料与方法:该前瞻性病例系列包括2012年2月至2015年6月间接受手术的42例Masquelet's诱导膜技术治疗的感染后节段性长骨缺损4-12 cm的患者。在第二阶段的骨移植过程中,将alone骨自体移植或与B-TCP颗粒(比率不超过1:1)混合使用,同时进行适当的内固定。评估了骨结合(在临床放射学上定义为在无支撑的情况下无痛地在患肢上承受重量的能力以及在X射线上桥接3个皮质)。结果:80.9%(34/42)接受指数植骨的患者实现了联合。仅使用自体移植的患者(15/15)和使用B-TCP的非吸烟型股骨不愈合患者(13/13)达到了100%的结合率。 B-TCP的使用与吸烟者(6 / 8,75%)和胫骨骨不连(4 / 9,55.5%)的骨不连率更高有关。在第二骨移植手术后,除8名骨不连患者外,所有患者中只有1个人联合了。结论:B-TCP是Masquelet感染后长节段性骨不连的两阶段治疗的一种有效且安全的自体骨移植扩展剂。应向患者提供有关骨不连的风险增加以及使用后需要再次植骨的咨询,尤其是如果吸烟者或受累部位为胫骨。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号